Glaxo Group Limited

Cephalon, Inc.

Teva Pharmaceuticals Australia Pty Ltd

Aprogen Inc.

Cephalon Australia Pty. Ltd.

Aprogen Kic Inc.

Cephalon Australia (Vic) Pty Ltd

Evogenix, Ltd.

George Kopsidas

Vincent Batori

Anthony Gerard Doyle

Adam Clarke

Lynn Dorothy Poulton

Philip Anthony Jennings

Andrew James Pow

Matthew Pollard

Sangsoon Yoon

David S Wilson, Jr

Kwon Pyo Hong

Debra Tamvakis

Gregory Coia

Merilyn Sleigh

Briony Cristiano

Anthony Roberts

Irene Koukoulas

Jonathan Henry Ellis

Volker Germaschewski

Paul Andrew Hamblin

Ruth McAdam

Stephanie Jane Clegg

Rabinder Kumar Prinjha

Bernadette Wai

Ruth Mcadam

Adam William Clarke

The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.

Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases

Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.

Anti-CD43 antibody and use thereof for cancer treatment

Antibodies against TL1a and uses thereof

The present invention provides an antibody comprising an antigen binding domain which binds to human IL-12 and human IL-23. The antibody binds human IL-12p40 existing as a monomer (human IL-12p40) and as a homodimer (human IL-12p80) and the antibody inhibits the binding of human IL-12 to human IL-12R &#x3b2;2 and human IL-23 to human IL-23R but does not inhibit the binding of human IL-12 or human IL-23 or human IL-12p40 or human IL-12p80 to human IL-12R&#x3b2;1.

Anti-IL-12/IL-23 antibodies

The present invention relates to novel osteoprotegerin variant proteins (GYPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these GYPs are also provided. Recombinant vectors and host cells expressing these GYPs are also encompassed as are methods of producing recombinant GYPs. The present invention also relates to compositions comprising these GYPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The GYPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.

Osteoprotegerin variant proteins

The present invention relates to antibodies to NOGO, pharmaceutical formulations containing them and to the use of such antibodies in the treatment and/or prophylaxis of neurological diseases/disorder.

Immunoglobulins

The present invention relates to novel osteoprotegerin variant proteins (OVPs) that demonstrate reduced binding affinity for their ligand TRAIL when compared to wild-type osteoprotegerin. Nucleic acids which encode these OVPs are also provided. Recombinant vectors and host cells expressing these OVPs are also encompassed as are methods of producing recombinant OVPs. The present invention also relates to compositions comprising these OVPs, and to methods of treating bone diseases characterised by increased bone turnover and/or loss. The OVPs of the invention are useful for preventing bone resorption and may be used to treat any condition resulting in abnormal bone turnover or bone loss such as osteoporosis, hypercalcemia, Paget's disease of bone, multiple myeloma, bone cancer and bone loss due to rheumatoid arthritis or osteomyelitis, and the like.

Growing community of inventors

Preston, Australia

George Kopsidas